PMID- 25164472
OWN - NLM
STAT- MEDLINE
DCOM- 20150727
LR  - 20161125
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 17
IP  - 12
DP  - 2014 Dec
TI  - Cost of adverse events during treatment with everolimus plus exemestane or 
      single-agent chemotherapy in patients with advanced breast cancer in Western 
      Europe.
PG  - 837-45
LID - 10.3111/13696998.2014.959589 [doi]
AB  - OBJECTIVE: Treatment options for recurrent or progressive hormone 
      receptor-positive (HR+) advanced breast cancer include chemotherapy and 
      everolimus plus exemestane (EVE + EXE). This study estimates the costs of 
      managing adverse events (AEs) during EVE + EXE therapy and single-agent 
      chemotherapy in Western Europe. METHODS: An economic model was developed to 
      estimate the per patient cost of managing grade 3/4 AEs for patients who were 
      treated with EVE + EXE or chemotherapies. AE rates for patients receiving 
      EVE + EXE were collected from the phase III BOLERO-2 trial. AE rates for 
      single-agent chemotherapy, capecitabine, docetaxel, or doxorubicin were collected 
      from published clinical trial data. AEs with at least 2% prevalence for any of 
      the treatments were included in the model. A literature search was conducted to 
      obtain costs of managing each AE, which were then averaged across Western 
      European countries (when available). Per patient costs for managing AEs among 
      patients receiving different therapies were reported in 2012 euros (euro). RESULTS: 
      The EVE + EXE combination had the lowest average per patient cost of managing AEs 
      (euro730) compared to all chemotherapies during the first year of treatment 
      (doxorubicin: euro1230; capecitabine: euro1721; docetaxel: euro2390). The most costly 
      adverse event among all patients treated with EVE + EXE was anemia (on average 
      euro152 per patient). The most costly adverse event among all patients treated with 
      capecitabine, docetaxel, or doxorubicin was lymphocytopenia (euro861 per patient), 
      neutropenia (euro821 per patient), and leukopenia (euro382 per patient), respectively. 
      CONCLUSIONS: The current model estimates that AE management during the treatment 
      of HR+ advanced breast cancer will cost one-half to one-third less for EVE + EXE 
      patients than for chemotherapy patients. The consideration of AE costs could have 
      important implications in the context of healthcare spending for advanced breast 
      cancer treatment.
FAU - Campone, Mario
AU  - Campone M
AD  - Centre Rene Gauducheau, Service Oncologie Medicale , Nantes Saint-Herblain , 
      France.
FAU - Yang, Hongbo
AU  - Yang H
FAU - Faust, Elizabeth
AU  - Faust E
FAU - Kageleiry, Andrew
AU  - Kageleiry A
FAU - Signorovitch, James E
AU  - Signorovitch JE
FAU - Zhang, Jie
AU  - Zhang J
FAU - Gao, Haitao
AU  - Gao H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140918
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Androstadienes)
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - NY22HMQ4BX (exemestane)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Androstadienes/administration & dosage/adverse effects/*economics
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*economics
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/economics
MH  - Breast Neoplasms/*drug therapy
MH  - Databases, Factual
MH  - Europe
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Models, Economic
MH  - Sirolimus/administration & dosage/adverse effects/*analogs & 
      derivatives/economics
OTO - NOTNLM
OT  - Adverse events
OT  - Chemotherapy
OT  - Costs and cost analysis
OT  - Everolimus
OT  - Exemestane
OT  - Metastatic breast cancer
EDAT- 2014/08/29 06:00
MHDA- 2015/07/28 06:00
CRDT- 2014/08/29 06:00
PHST- 2014/08/29 06:00 [entrez]
PHST- 2014/08/29 06:00 [pubmed]
PHST- 2015/07/28 06:00 [medline]
AID - 10.3111/13696998.2014.959589 [doi]
PST - ppublish
SO  - J Med Econ. 2014 Dec;17(12):837-45. doi: 10.3111/13696998.2014.959589. Epub 2014 
      Sep 18.